Treatment with vorinostat (HDAC inhibitor) and tranylcypromine (histone lysine demethylase KDM1A inhibitor) (Figure 2) decreased GBM stem cell proliferation and led to significant tumor regression in mouse models [166]. This evidence concerns the gene KDM1A and neoplasm.